[P3-51] Efficacy and tolerability of perampanel in adolescents with drug-resistant focal epilepsy
Purpose: Perampanel, a selective noncompetitive antagonist at the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, is a novel, orally active new antiepileptic drug. Clinical experience with perampanel is still limited. We aimed to establish the short term efficacy and tolerability of perampanel in adolescents.
Methods: From March 2016 to August 2016, 81 patients, aged 12 years or older received perampanel as an adjunctive therapy for drug-resistant focal epilepsy at Severance Children’s Hospital. Three-month outcomes and side effects were assessed with medical chart review.
Results: Of 81, 44 were male patients. Mean age was 17.6 ± 4.4 years old. Common etiologies included malformations of cortical development (17, 21%), and hypoxic ischemic encephalopathy (11, 14%). Mean number of concomitant antiepileptic drugs was 4.9 ± 1.1. Maximum follow-up duration was 5 months. After 3 months of perampanel therapy, 9 (11%) patients became seizure free, and additional 28 (35%) patients experienced more than 50% seizure reduction. In 6 (7%) patients, however, seizures became worse. Of 81, 46 (57%) patients experienced side effects. Dizziness or lethargy (33%), aggressive behavior or mood changes (21%), gait disturbance (20%), sleep related problems (12%) were the most common side effects. Twenty (25%) patients discontinued perampanel in the initial 3 months after the therapy was initiated. Eleven (14%) patients discontinued due to the side effects, 9 (11%) due to ineffectiveness.
Conclusion: Our study suggests that perampanel is an effective and safe therapeutic option for adolescents with drug-resistant epilepsy.
Methods: From March 2016 to August 2016, 81 patients, aged 12 years or older received perampanel as an adjunctive therapy for drug-resistant focal epilepsy at Severance Children’s Hospital. Three-month outcomes and side effects were assessed with medical chart review.
Results: Of 81, 44 were male patients. Mean age was 17.6 ± 4.4 years old. Common etiologies included malformations of cortical development (17, 21%), and hypoxic ischemic encephalopathy (11, 14%). Mean number of concomitant antiepileptic drugs was 4.9 ± 1.1. Maximum follow-up duration was 5 months. After 3 months of perampanel therapy, 9 (11%) patients became seizure free, and additional 28 (35%) patients experienced more than 50% seizure reduction. In 6 (7%) patients, however, seizures became worse. Of 81, 46 (57%) patients experienced side effects. Dizziness or lethargy (33%), aggressive behavior or mood changes (21%), gait disturbance (20%), sleep related problems (12%) were the most common side effects. Twenty (25%) patients discontinued perampanel in the initial 3 months after the therapy was initiated. Eleven (14%) patients discontinued due to the side effects, 9 (11%) due to ineffectiveness.
Conclusion: Our study suggests that perampanel is an effective and safe therapeutic option for adolescents with drug-resistant epilepsy.